Literature DB >> 12611829

Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder.

Alessandro Bertolino1, Domenico Sciota, Flora Brudaglio, Mario Altamura, Giuseppe Blasi, Antonello Bellomo, Nicola Antonucci, Joseph H Callicott, Terry E Goldberg, Tommaso Scarabino, Daniel R Weinberger, Marcello Nardini.   

Abstract

OBJECTIVE: The authors used proton magnetic resonance spectroscopic imaging ((1)H-MRSI) to assess potential reductions of N-acetylaspartate (a marker of neuronal integrity) in the hippocampal area and dorsolateral prefrontal cortex of patients with schizophreniform disorder. In addition, they assessed the relationship between N-acetylaspartate levels and working memory deficits.
METHOD: Twenty-four patients with DSM-IV schizophreniform disorder and 24 healthy subjects were studied. Subjects underwent (1)H-MRSI and were given the N-back working memory test.
RESULTS: The schizophreniform disorder patients had selective reductions of N-acetylaspartate ratios in the hippocampal area and the dorsolateral prefrontal cortex, and a positive correlation was seen between N-acetylaspartate ratios in the dorsolateral prefrontal cortex and performance during the 2-back working memory condition.
CONCLUSIONS: Similar to findings reported in schizophrenia studies, N-acetylaspartate reductions in the hippocampal area and the dorsolateral prefrontal cortex were seen in patients with schizophreniform disorder. Moreover, the results support other evidence that neuronal pathology in the dorsolateral prefrontal cortex accounts for a proportion of working memory deficits already present at illness outset.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611829     DOI: 10.1176/appi.ajp.160.3.483

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  16 in total

1.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

2.  Regulation of cognitive resources during an n-back task in youth-onset psychosis and attention-deficit/hyperactivity disorder (ADHD).

Authors:  Canan Karatekin; Christopher Bingham; Tonya White
Journal:  Int J Psychophysiol       Date:  2009-05-07       Impact factor: 2.997

Review 3.  Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.

Authors:  Stephanie C Licata; Perry F Renshaw
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 4.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

5.  Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia.

Authors:  Meredith A Reid; Luke E Stoeckel; David M White; Kathy B Avsar; Mark S Bolding; N Shastry Akella; Robert C Knowlton; Jan A den Hollander; Adrienne C Lahti
Journal:  Biol Psychiatry       Date:  2010-06-08       Impact factor: 13.382

6.  Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia.

Authors:  Ronald R Seese; Joseph O'Neill; Matthew Hudkins; Prabha Siddarth; Jennifer Levitt; Ben Tseng; Keng Nei Wu; Rochelle Caplan
Journal:  Schizophr Res       Date:  2011-08-27       Impact factor: 4.939

Review 7.  [Magnetic resonance spectroscopy in schizophrenia. Possibilities and limitations].

Authors:  T Wobrock; H Scherk; P Falkai
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

8.  Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Authors:  L Fredrik Jarskog; Zhengchao Dong; Alayar Kangarlu; Tiziano Colibazzi; Ragy R Girgis; Lawrence S Kegeles; Deanna M Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; Michael P Harms; Daniel C Javitt; Richard Se Keefe; Joseph P McEvoy; Robert P McMahon; Stephen R Marder; Bradley S Peterson; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2013-01-16       Impact factor: 7.853

9.  Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study.

Authors:  Jeffrey A Stanley; Madhuri Vemulapalli; Jeffrey Nutche; Debra M Montrose; John A Sweeney; Jay W Pettegrew; Frank P MacMaster; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2007-05-10       Impact factor: 4.939

Review 10.  T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

Authors:  Bethany K Bracken; Elizabeth D Rouse; Perry F Renshaw; David P Olson
Journal:  Psychiatry Res       Date:  2013-06-12       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.